25(OH) VITAMIN D DEFICIENCY IN CYSTIC FIBROSIS CHILDREN – A
PROSPECTIVE STUDY ON PREVALENCE AND TREATMENT
OUTCOME
IUSTINA VIOLETA STAN 1,2#, ANCA BĂLĂNESCU 1,2, IOANA FLORENTINA CODREANU 1,2*, ALINA ANGELICA BELIVACA 1,2, MIRELA ELENA RITIVOIU 1,2#, MARIANA MĂDĂLINA DRĂGOI 2, SILVIU ADRIAN MARINESCU 1,3#, CHANER ALI 2, VALENTINA DANIELA COMĂNICI 1,2
1“Carol Davila” University of Medicine and Pharmacy, 8 Eroii Sanitari Boulevard, Bucharest, Romania
2“Alessandrescu-Rusescu” Mother and Child’s Health National Institute, 120 Lacul Tei Boulevard, Bucharest, Romania
3“Bagdasar-Arseni” Emergency Clinical Hospital, Department of Plastic and Reconstructive Surgery, 12 Berceni Road,
Bucharest, Romania
*corresponding author: dr.ioanacodreanu@gmail.com
#Authors with equal contribution
Download Full Article

Abstract:
Cystic fibrosis (CF) patients have a high risk of vitamin D deficiency due to malabsorption. The aim of the study was to
evaluate the prevalence of 25(OH) vitamin D deficiency in a paediatric CF cohort and the outcome of vitamin D3 treatment.
We conducted a prospective “before-after” cohort study on 65 children diagnosed with CF. Patient assessment included
anthropometric measurements, pulmonary function tests and serum vitamin D level assessment at visit one and 6 months later
at visit 2 for patients with vitamin D deficiency. A serum level below 74 nmol/L was considered vitamin D deficiency. The
study revealed a high prevalence of vitamin D3 deficiency (61.6%) in CF patients. Treatment with high doses of vitamin D3
had a good therapeutic response with statistically significant changes of serum levels of 25(OH) vitamin D, but not with the
expected efficiency.

Top